Breaking the ground for WuXi STA’s new pharmaceutical facility in Delaware
WuXi AppTec subsidiary and leading CRDMO, WuXi STA, has broken the ground at the site for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware.
WuXi STA, a subsidiary of WuXi AppTec based in Shanghai, China, have broken the ground for their latest 190-acre pharmaceutical manufacturing campus in Middletown Delaware. The project was announced in June 2021 and promises WuXi STA’s second facility in the United States to offer expanded capacity and greater flexibility for their customers.
The new, state-of-the-art facility will offer approximately 500 full-time jobs by 2026, and provide a site for formulation development, clinical and commercial drug product manufacturing services in addition to packaging, labelling and storage and distribution for clinical trial and commercial drug materials and products. With 12 sites across the United States, Europe, and Asia, WuXi STA hopes to continue offering their services across the globe.
WuXi STA specializes in pharmaceutical development and manufacturing capabilities, offering solutions for integrated chemical, manufacturing, and controls as a premier CRDMO. Parent company WuXi AppTec operates with a global portfolio of research and development and manufacturing services for the pharmaceutical and healthcare industries to advance discoveries and manufacturing, delivering essential therapies to patients.
Delaware Governor John Carney commented: “The biopharmaceutical industry is part of Delaware’s DNA… Over the next 5 years, WuXi STA plans to build a state-of-the-art pharmaceutical manufacturing campus in one of Delaware’s fastest-growing communities, bringing with it good jobs and economic growth.”
Minzhang Chen, co-CEO of WuXi AppTec and CEO of WuXi STA, added: “I would like to thank our federal, state, and local partners in Delaware for their continued support in the establishment of this site… WuXi STA continues to increase our capabilities and capacities to better serve our customers through a more robust and reliable supply chain. With our integrated contract research, development, and manufacturing organization platform and proven quality system, we look forward to working with our customers to swiftly deliver their innovative therapies to market in order to save lives and improve healthcare for patients.
Source: WuXi STA (stapharma.com)
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
.png)
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance